Further to DrugAlert volume 808, HPS Pharmacies wish to advise that multiple suppliers are experiencing a supply interruption for amoxicillin products, as follows.
| Product | ARTG | Current Status |
| Alphamox 500mg capsules | 17679 | Early December 2022 |
| Amiloxyn 500mg capsules | 185798 | Late November 2022 |
| Amoxycillin Generichealth 500mg capsules | 207005 | Late February 2023 |
| Amoxycillin Sandoz 500mg capsules | 63333 | Late November 2022 |
| APO-Amoxycillin 500mg capsules | 208144 | Early December 2022 |
| Maxamox 1000mg tablets | 76050 | Early December 2022 |
| APO-Amoxycillin 125mg/5ml Suspension | 137882 | Early January 2023 |
| Amoxil 125mg/5ml Syrup | 11133 | Mid-November 2022 |
| APO-Amoxycillin 250mg/5ml Suspension | 137883 | Early February 2023 |
| Amoxycillin Sandoz 250mg/5ml Suspension | 93720 | Mid-December 2022 |
| Amoxil Forte 250mg/5ml Syrup | 11134 | Mid-November 2022 |
| Maxamox 500mg/5ml Suspension | 93722 | Late December 2022 |
Internationally registered brands of amoxicillin 250mg/5mL suspension and 500mg capsules have been approved for supply under Section 19A of the Therapeutic Goods Act 1989.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact your pharmacist at HPS Pharmacies.
Subscribe Knowledge Centre Updates
Enter your details to receive Knowledge Centre updates